ArticlePatient related outcome measures2026
Validation of a respiratory symptom score from the Quality of Life-Bronchiectasis Questionnaire in adults with
Article in Patient related outcome measures, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the psychometric properties of a respiratory symptom score from the Quality of Life-Bronchiectasis Questionnaire in adults with Methods: Structural validity, internal consistency, test-retest reliability, and known-groups validity were assessed using data from the ARISE (NCT04677543) and ENCORE (NCT04677569) phase 3 trials. Convergent validity was assessed using Exacerbations of Chronic Pulmonary Disease Tool (EXACT), EXACT Respiratory Symptoms (E-RS), St. George Respiratory Questionnaire (SGRQ), and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. Anchor-based meaningful within-patient change (MWPC) thresholds were estimated using the Patient Global Impression of Severity Respiratory scale. Results: In total, 362 patients were included for cross-sectional (ARISE: 97, ENCORE: 265) and longitudinal (ARISE: 99) validation analyses. Modern psychometric methods supported item relevance and an essentially unidimensional mean score. The respiratory symptom score demonstrated adequate internal consistency (McDonald's omega: 0.86, Cronbach's alpha: 0.81), test-retest reliability (intraclass correlation coefficient: 0.73), convergent validity (EXACT: -0.72, E-RS: -0.72, SGRQ: -0.77, FACIT-Fatigue: 0.51), and known-groups validity. The estimated MWPC threshold was a 16.67-point median change from baseline (95% CI: 8.33-16.83 points). Conclusions: The respiratory symptom score is a robust, sensitive, and responsive measure of respiratory symptoms in adults with a new or recurrent MAC lung disease diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.